Life Sciences

  • April 17, 2026

    Doc Says Texas Man Can't Sue Over Mailed Abortion Pills

    A Texas man suing his ex-girlfriend's out-of-state doctor for prescribing mail-order abortion pills can't prove that the doctor caused the wrongful death of their unborn child, the doctor told a federal court, saying the case should be dismissed because he's not responsible for the woman's actions. 

  • April 17, 2026

    Fed. Circ. Reverses $18M Penile Implant Trade Secret Win

    In a unanimous precedential decision, the Federal Circuit on Friday largely reversed a California jury's $18.3 million trade secret verdict over a penile implant, holding that the asserted secrets were already publicly disclosed or generally known and therefore not protectable.

  • April 16, 2026

    Trump Taps Ret. Rear Admiral Schwartz As New CDC Chief

    President Donald Trump on Thursday nominated Dr. Erica Schwartz, a retired rear admiral who served in the U.S. Coast Guard and as deputy surgeon general in the first Trump administration, to be the Centers for Disease Control and Prevention's next director.

  • April 16, 2026

    Wis. Supreme Court Upholds Pabst Asbestos Verdict

    The Wisconsin Supreme Court upheld a verdict in favor of the estate of a steamfitter exposed to asbestos through his work at a Pabst Brewing Co. brewery, saying Wednesday that the company still owed a duty of care to employees of independent contractors, but capped punitive damages to about $4.65 million.

  • April 16, 2026

    Fed. Circ. Says Judge Wrongly Axed Teva's $177M Eli Lilly Win

    The Federal Circuit ruled Thursday that a Massachusetts federal judge was wrong to overturn a $177 million jury verdict that Teva won against Eli Lilly & Co. on headache drug patents, finding that contrary to the judge's finding, the patents are not invalid.

  • April 16, 2026

    IV Device Redesign Not Enough To Lift Ban, CBP Says

    A U.S. medical device company's redesigned products used for intravenous drips are still barred from importation into the country, U.S. Customs and Border Protection said in an order released Thursday, with the agency unconvinced the new versions aren't still patent-infringing.

  • April 16, 2026

    USPTO Ends COVID Patent Appeals Program

    The U.S. Patent and Trademark Office has decided to end a program launched five years ago that aimed to prioritize and fast-track ex parte appeals of rejections on patent applications for inventions related to combating COVID-19.

  • April 16, 2026

    Katten Partner Rejoins Epstein Becker In DC For 3rd Time

    Epstein Becker Green LLP has rehired, for the third time, a healthcare transactional attorney who focuses his practice on guiding hospital systems, private equity-backed entities and professional practices on transactional matters and regulatory compliance.

  • April 15, 2026

    Consumer Cases Drive Class Action Spike, Report Says

    Federal class action filings spiked in 2025 after nearly a decade of relative stability, fueled by a surge in consumer protection lawsuits tied to data breaches, digital commerce and online accessibility claims, according to a new report from Lex Machina.

  • April 15, 2026

    Amneal Trims But Can't Nix AGs' Drug Price-Fixing Suit

    There is enough evidence from which a jury could conclude that Amneal Pharmaceuticals participated in a conspiracy to fix the price of an epilepsy medication, but not enough to show it participated in the overarching antitrust conspiracy alleged by dozens of state attorneys general, a Connecticut federal judge ruled Wednesday.

  • April 15, 2026

    Drugmaker Aquestive's Brass Sued Over FDA Setback

    Executives and directors of pharmaceutical company Aquestive Therapeutics Inc. were hit with a shareholder's derivative suit Wednesday accusing them of ignoring deficiencies in a research study for Aquestive's allergic reaction treatment, which eventually prompted the U.S. Food and Drug Administration to reject the company's new drug application.

  • April 15, 2026

    Ex-DOJ Antitrust Atty On Google Case Joins Wilson Sonsini

    A lead attorney on the U.S. Department of Justice Antitrust Division's monopolization cases against Google LLC who left the agency last week joined Wilson Sonsini Goodrich & Rosati PC in Washington, D.C., on Wednesday as a partner.

  • April 15, 2026

    Squires Passes On 10 Patent Challenges, Takes On 2 Others

    The newest bulk order from U.S. Patent and Trademark Office Director John Squires has rejected 10 petitions for America Invents Act patent reviews while granting a couple others, including a Google challenge to a patent owned by Headwater Research LLC.

  • April 15, 2026

    NC Judge Won't Undo $4M Philips Copyright Verdict

    A North Carolina federal judge has refused to erase a $4 million jury verdict against independent service organization Transtate Equipment Co. for violations of the Digital Millennium Copyright Act, saying trial evidence provided a "firm basis" to support the jury's statutory damages award.

  • April 15, 2026

    Willkie Adds O'Melveny Litigator To Los Angeles Office

    Willkie Farr & Gallagher LLP expanded its Los Angeles office with the recent addition of a litigator who moved her practice after nearly 15 years with O'Melveny & Myers LLP.

  • April 15, 2026

    Biopharma Co. Says Ex-Worker Used Files To Build AI Rival

    A biopharmaceutical consulting firm's ex-contractor illegally downloaded thousands of proprietary internal files and emails that he then used to launch a rival company powered by artificial intelligence, the firm claimed in a lawsuit, alleging that the former contractor violated federal trade secrets law.

  • April 14, 2026

    Armistice Capital Used COVID To Juice Vaxart Stock, Jury Told

    Hedge fund Armistice Capital and two of its executives exploited the COVID-19 pandemic to issue press releases that falsely inflated their controlling share in pharmaceutical company Vaxart, then dumped the shares for $250 million before the bottom fell out, investors told a California federal jury at the start of trial Tuesday.

  • April 14, 2026

    4th Circ. Revives Pharma Bid To Block Maryland's 340B Law

    A split Fourth Circuit panel on Tuesday tossed a Maryland district court's order denying a preliminary injunction to pharmaceutical manufacturers that have challenged a state law addressing drug delivery in the federal 340B discount program, pointing to its recent ruling that West Virginia's similar statute is likely preempted.

  • April 14, 2026

    States Denied Time For Talks To Settle Drug Price-Fixing Suit

    A Connecticut federal judge Tuesday denied a request by dozens of U.S. states to freeze their antitrust case against generic-drug manufacturers, a pause the states argued would allow the parties to focus on settlement talks rather than pending discovery and motion deadlines.

  • April 14, 2026

    Justices Told That Eli Lilly's FCA Qui Tam Challenge Too Late

    A whistleblower who secured a $183 million trial win against Eli Lilly urged the U.S. Supreme Court on Tuesday to reject its constitutional challenge over his ability to sue for the federal government, arguing the drugmaker's arguments came too late.

  • April 14, 2026

    Trade Group Latest To Sue Wash. Over 340B Drug Pricing Law

    Pharmaceutical Research and Manufacturers of America claims a new Washington state law attempts to illegally reshape the federal 340B Drug Pricing Program and singles out participating drugmakers with burdensome regulations, according to a fresh federal lawsuit that follows similar constitutional challenges mounted by Novartis and AbbVie.

  • April 14, 2026

    Vertex Sues Former Exec To Block Move To Rival

    Vertex Pharmaceuticals asked a Massachusetts state court judge to bar a former executive from taking a virtually identical role at competitor Vera Therapeutics, citing a noncompete agreement he allegedly signed.

  • April 14, 2026

    FDA Offers Guidance On Safety Testing For Gene-Editing Tech

    The U.S. Food and Drug Administration on Tuesday issued draft guidance recommending steps drug companies should take to evaluate the safety of gene-editing technology as they seek federal approval for cutting-edge treatments aimed at genetic diseases.

  • April 14, 2026

    3rd Circ. Upholds J&J Injunction Bid Loss In Biosimilar Fight

    The Third Circuit on Tuesday ruled that a Johnson & Johnson subsidiary couldn't justify its bid for an order blocking Samsung Bioepis from paving the way for a Cigna unit to launch a generic version of an anti-inflammatory treatment.

  • April 14, 2026

    Eli Lilly To Purchase Cooley-Led CrossBridge In $300M Deal

    Venture-backed pre-clinical biotechnology firm CrossBridge Bio Inc., advised by Cooley LLP, on Tuesday announced that it has agreed to be bought by pharmaceutical giant Eli Lilly & Co. in a deal worth up to $300 million.

Expert Analysis

  • Series

    Law School's Missed Lessons: How To Start A Law Firm

    Author Photo

    Launching and sustaining a law firm requires skills most law schools don't teach, but every lawyer should understand a few core principles that can make the leap calculated rather than reckless, says Sam Katz at Athlaw.

  • Fed. Circ. Patent Decisions In 2025: An Empirical Review

    Author Photo

    In 2025, the Federal Circuit's increased output was not enough to keep up with its ever-growing patent case load, and patent owners and applicants fared poorly overall as the court's affirmance rate fell, says Dan Bagatell at Perkins Coie.

  • Regulatory Uncertainty Ahead For Organ Transplant System

    Author Photo

    Pending court cases against a Centers for Medicare and Medicaid Services final rule that introduced a competition-centric model for assessing organ procurement organizations' performance will significantly influence the path forward for such organizations and transplant hospitals, say attorneys at Crowell & Moring.

  • Key False Claims Act Trends From The Last Year

    Author Photo

    The False Claims Act remains a powerful enforcement tool after some record verdicts and settlements in 2025, and while traditional fraud areas remain a priority, new initiatives are raising questions about its expanding application, says Veronica Nannis at Joseph Greenwald.

  • Opinion

    It's Too Soon To Remove Suicide Warnings From GLP-1 Drugs

    Author Photo

    The U.S. Food and Drug Administration's decision this month to order removal of warnings about the risk of suicidal thoughts from GLP-1 weight-loss drugs is premature — and from a safety and legal standpoint, the downside of acting too soon could be profound, says Sean Domnick at Rafferty Domnick.

  • Series

    Hosting Exchange Students Makes Me A Better Lawyer

    Author Photo

    Opening my home to foreign exchange students makes me a better lawyer not just because prioritizing visiting high schoolers forces me to hone my organization and time management skills but also because sharing the study-abroad experience with newcomers and locals reconnects me to my community, says Alison Lippa at Nicolaides Fink.

  • FDA's 2025 Enforcement Scorecard Highlights Data Focus

    Author Photo

    The U.S. Food and Drug Administration's increased enforcement activity in 2025 was driven by artificial intelligence and a focus on foreign manufacturers, necessitating proactive compliance strategies for an environment that is increasingly reliant on data, say attorneys at Reed Smith.

  • How A 1947 Tugboat Ruling May Shape Work Product In AI Era

    Author Photo

    Rapid advances in generative artificial intelligence test work-product principles first articulated in the U.S. Supreme Court’s nearly 80-year-old Hickman v. Taylor decision, as courts and ethics bodies confront whether disclosure of attorneys’ AI prompts and outputs would reveal their thought processes, say Larry Silver and Sasha Burton at Langsam Stevens.

  • Navigating Privilege Law Patchwork In Dual-Purpose Comms

    Author Photo

    Three years after the U.S. Supreme Court declined to resolve a circuit split in In re: Grand Jury, federal courts remain split as to when attorney-client privilege applies to dual-purpose legal and business communications, and understanding the fragmented landscape is essential for managing risks, say attorneys at Covington.

  • How AI Drafting Should Transform Patent Filing Strategies

    Author Photo

    As agentic artificial intelligence reduces the time and expense required to draft and file patents, companies should shift focus away from rationing drafting hours and more toward governing optionality, says Ian Schick at Paximal.

  • 5 Advertising Law Trends That Will Shape 2026

    Author Photo

    The legal landscape for advertisers will grow only more complex this year, with ongoing trends including a federal regulatory retreat, more aggressive action by the states, a focus on child privacy and expanded scrutiny of "natural" claims, say attorneys at Reed Smith.

  • Cannabis Industry Faces An Inflection Point This Year

    Author Photo

    Cannabis industry developments last year — from the passage of a new wholesale tax in Michigan, to an executive order accelerating the federal rescheduling process — presage a more mature phase of legalization this year, with hardening expectations and enforcement to come, says Alex Leonowicz at Howard & Howard.

  • Series

    Fly-Fishing Makes Me A Better Lawyer

    Author Photo

    Much like skilled attorneys, the best anglers prize preparation, presentation and patience while respecting their adversaries — both human and trout, says Rob Braverman at Braverman Greenspun.

  • 4 Ways GCs Can Manage Growing Service Of Process Volume

    Author Photo

    As automation and arbitration increase the volume of legal filings, in-house counsel must build scalable service of process systems that strengthen corporate governance and manage risk in real time, says Paul Mathews at Corporation Service Co.

  • Series

    The Law Firm Merger Diaries: Forming Measurable Ties

    Author Photo

    Relationship-building should begin as early as possible in a law firm merger, as intentional pathways to bringing people together drive collaboration, positive client response, engagements and growth, says Amie Colby at Troutman.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.